Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
4DMedical Ltd ( (AU:4DX) ) has issued an update.
4DMedical Ltd reported a significant increase in its operating revenue for FY2025, reaching $5.9 million, a 56% rise from the previous year. This growth was primarily driven by its SaaS offerings, which contributed $5.7 million. Despite the increase in revenue, the company still reported a net loss of $30.1 million, although this was an improvement from the previous year. The company also noted a substantial gain from the remeasurement of contingent consideration liability due to its acquisition of Imbio. Operating expenses slightly increased due to higher investment in commercialization, which was partially offset by reduced consultancy and travel costs.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Ltd operates in the medical technology industry, focusing primarily on providing innovative Software-as-a-Service (SaaS) solutions. The company’s market focus is on enhancing medical imaging and diagnostics through advanced technology.
Average Trading Volume: 1,654,075
Technical Sentiment Signal: Buy
Current Market Cap: A$253.7M
For an in-depth examination of 4DX stock, go to TipRanks’ Overview page.